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Abstract
Introduction: No definitive data are available regarding the value of switching to an alternative
TNF antagonist in rheumatoid arthritis patients who fail to respond to the first one. The aim of this
study was to evaluate treatment response in a clinical setting based on HAQ improvement and
EULAR response criteria in RA patients who were switched to a second or a third TNF antagonist
due to failure with the first one.
Methods: This was an observational, prospective study of a cohort of 417 RA patients treated
with TNF antagonists in three university hospitals in Spain between January 1999 and December
2005. A database was created at the participating centres, with well-defined operational
instructions. The main outcome variables were analyzed using parametric or non-parametric tests
depending on the level of measurement and distribution of each variable.
Results: Mean (± SD) DAS-28 on starting the first, second and third TNF antagonist was 5.9 (±
2.0), 5.1 (± 1.5) and 6.1 (± 1.1). At the end of follow-up, it decreased to 3.3 (± 1.6; Δ = -2.6; p >
0.0001), 4.2 (± 1.5; Δ = -1.1; p = 0.0001) and 5.4 (± 1.7; Δ = -0.7; p = 0.06). For the first TNF
antagonist, DAS-28-based EULAR response level was good in 42% and moderate in 33% of patients.
The second TNF antagonist yielded a good response in 20% and no response in 53% of patients,
while the third one yielded a good response in 28% and no response in 72%. Mean baseline HAQ
on starting the first, second and third TNF antagonist was 1.61, 1.52 and 1.87, respectively. At the
end of follow-up, it decreased to 1.12 (Δ = -0.49; p < 0.0001), 1.31 (Δ = -0.21, p = 0.004) and 1.75
(Δ = -0.12; p = 0.1), respectively. Sixty four percent of patients had a clinically important
improvement in HAQ (defined as ≥ -0.22) with the first TNF antagonist and 46% with the second.
Conclusion: A clinically significant effect size was seen in less than half of RA patients cycling to a
second TNF antagonist.
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Background
Treatment with TNF antagonists has improved the out-
come of rheumatoid arthritis (RA) patients [1]. In both
early and established RA, two-thirds of patients achieve
meaningful clinical responses, yet one-third do not
respond. Additionally, a number of patients initially
responding develop acquired drug resistance or gradual
drug failure, and some have to discontinue the biologic
treatment due to adverse events. Overall, the 3-year reten-
tion rate of TNF antagonists in RA is around 65% [2].
TNF antagonists as a group have similar efficacy in RA,
although their effectiveness differs in other rheumatic dis-
eases. Moreover, case series and nonrandomized, open-
label observational studies in RA indicate that some
patients may fail to respond to one TNF inhibitor but will
respond to another. This is partially supported by data
showing that TNF antagonists differ in their pharmacoki-
netics and mechanisms of action [3]. Nevertheless, there
are no definitive data regarding the value of switching
between TNF antagonists. Another therapeutic option is
to switch to a different class of biologic agent such as ritux-
imab, tocilizumab or abatacept [4-6].
The aim of this study was to evaluate in a clinical setting
the clinical response based on evaluation of HAQ and
EULAR response criteria in RA patients with an insuffi-
cient response or loss of efficacy to the first TNF antago-
nist who were switched to a second or third one.
Methods
This was an observational, prospective study of a cohort of
417 RA patients treated with TNF antagonists in three uni-
versity hospitals in Spain between January 1999 and
December 2005. A database was created at the participat-
ing centres, with well-defined operational instructions.
Patients who had participated in clinical trials were
excluded.
Patients had been systematically evaluated at the initia-
tion of therapy and every three months thereafter. Patients
switching between TNF antagonists or switching to rituxi-
mab were evaluated on starting therapy and every 3
months thereafter. Evaluations included painful and
swollen joint counts, visual analogue scales of pain, glo-
bal health assessment by the patient and the physician,
ESR, C-reactive protein (CRP), Health Assessment Ques-
tionnaire (HAQ) and DAS-28 score. DAS-28-based
EULAR response was estimated. Data on the reason for
switching to a second TNF antagonist were recorded.
Descriptive statistics with central tendency and dispersion
measures were calculated. The main outcome variables
were analyzed using parametric or non-parametric tests
depending on the level of measurement and distribution
of each variable. A p-value < 0.05 (two tailed) was consid-
ered significant. Survival analysis was performed using
Kaplan-Meyer curves.
The study was conducted according to good clinical prac-
tice as applicable to epidemiological studies, which
ensures that the design, implementation and communica-
tion of data are reliable, and that patients' rights, integrity
and data confidentiality are protected. The study protocol
was approved by the Ethics Committee of the Hospital
Universitario Virgen Macarena which considered that
informed consent was not required due to the retrospec-
tive nature of the analysis of anonymous data.
Results
The initial TNF antagonist was infliximab (INF) in 238
cases (57%), etanercept (ETA) in 141 (34%), and adali-
mumab (ADA) in 38 (9%). Eighty-three patients had
switched to a second TNF antagonist and 18 to a third TNF
antagonist. Mean patient follow-up was 21.4 + 15.6
months, and TNF exposure was 443 patient-years for INF,
200.2 patient-years for ETA and 31.7 patient-years for
ADA. Switching in 48 cases (58%) was due to inefficacy,
in 24 cases (29%) to adverse events, and in 11 cases
(13%) to other reasons, primarily the doctor's or patient's
decision.
Relevant clinical data on the 417 patients (82% women)
are presented in table 1. The mean age of patients starting
their first TNF antagonist was 53 ± 13 years, and mean dis-
ease duration was 10.4 ± 8.2 years. Sixty-eight percent
were RF positive and 74% presented erosions. Three hun-
dred ninety-six patients (94%) received concomitant
DMARD; 324 methotrexate (MTX), 33 leflunomide (LF)
and 21 antimalarials. During follow up, 263 patients
(63%) continued the first TNF antagonist, 83 (20%)
switched to a second, and 18 (4%) to a third. Seventeen
percent of patients received no other biologic after discon-
tinuation. Forty-six patients treated with a second TNF
antagonist had switched from INF or ADA to ETA, 25 from
INF to ADA and 12 from ETA to ADA. Among patients
treated with a third TNF antagonist, 12 had changed from
ETA to ADA, 5 from ADA to ETA, and 1 from ETA to INF.
Mean DAS-28 on starting the first TNF antagonist was 5.9
± 2.0 and decreased to 3.3 ± 1.6, at the end of follow-up.
The improvement was statistically significant (Δ = -2.6; p
> 0.0001) for the whole group as well as for the three TNF
antagonists considered independently. DAS-28 on start-
ing the second TNF antagonist was 5.1 ± 1.5 and
decreased to 4.2 ± 1.5 at the end of follow-up (Δ = -1.1; p
= 0.0001). DAS-28 on starting the third TNF antagonist
was 6.1 ± 1.1 and decreased to 5.4 ± 1.7 at the end of fol-
low-up (Δ = -0.7; p = 0.06). The results are shown in
table 2.BMC Musculoskeletal Disorders 2009, 10:91 http://www.biomedcentral.com/1471-2474/10/91
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The DAS-28-based EULAR response level for the first TNF
antagonist was good in 42% of patients and moderate in
33%. For the second anti-TNF, good response was
achieved in 20% of cases and 53% failed to respond. For
the third TNF antagonist, 26% of cases had a good
response and 72% failed to respond (Table 2). Response
to the second TNF antagonist did not differ significantly
(p = 0.5) by the reason for switching (Table 3).
HAQ improved significantly (Table 2) with use of the first
TNF antagonist, with a mean baseline score of 1.61 and
final score of 1.12 (Δ = -0.49; p < 0.0001), with 64% of
patients showing an improvement ≥ -0.22. Improvement
was not significantly different with the three biologics. For
the second TNF antagonist, mean initial and final HAQ
were 1.52 and 1.31, respectively (Δ = -0.21, p < 0.004),
with 46% of patients showing an improvement ≥ -0.22.
For the third TNF antagonist, HAQ scores were 1.87 and
1.75 at the initial and final evaluation, respectively (Δ = -
0.12; p = 0.1). The mean cumulative change in HAQ from
pre-treatment with the first TNF antagonist is depicted in
figure 1.
Retention rates with the first TNF antagonist were 80%,
62%, 53% and 34% at 12, 24, 36 and 60 months, respec-
tively. No significant differences were found among the
three drugs (p = 0.1). The reasons for discontinuation
were inefficacy (40%), adverse events (40%) and other
(20%). Retention rates with the second TNF antagonist
were 70%, 60% and 47% at 12, 24 and 36 months, respec-
tively. Twenty-five patients discontinued the biologic,
most commonly due to inefficacy (77%). Only 9 of the 18
patients switching to a third TNF antagonist retained the
biologic at 6 months. Six stopped the biologic due to inef-
ficacy.
Fifty-four patients had a severe adverse event during treat-
ment with the first TNF antagonist. Infusion reaction was
the most frequent adverse event, occurring in 16 patients
treated with INF, followed by urticaria or severe skin rash
in 9 patients, and upper respiratory tract infection in 8.
Other less frequent adverse events were congestive heart
failure, tuberculosis, herpes zoster infection, acute pancre-
atitis, cutaneous vasculitis and lupus-like syndrome.
Seven patients had severe adverse events while treated
with the second TNF antagonist (Table 4).
Discussion
In the present study we describe relevant outcomes in clin-
ical practice in RA patients failing to respond to one TNF
antagonist and switching to another, in comparison with
RA patients who retain the first antagonist. Our data show
that a number of patients switching between TNF antago-
nists may attain a significant response, yet a large propor-
Table 1: Characteristics of patients switching between TNF antagonists
1st TNF antagonist (417) 2nd TNF antagonist (83) 3rd TNF antagonist (18)
Age, years (SD) 53 ± 13 52 ± 12 44 ± 11
Gender (F) 342 (82%) 68(82%) 17(94%)
Disease duration years (SD) 10.4 (± 8,2) 10 (± 8) 11(± 8)
RF positive, % 68% 69% 61%
Radiographic erosions, % 74% 79% 94%
Concomitant DMARD, % 94% 94% 100%
Methotrexate 78% 71% 50%
Leflunomide 8% 2% 17%
Antimalarial 5% 4% 5%
Oral glucocorticoids, % 83% 83% 51%
Adalimumab, n 38 36 12
Etanercept, n 141 46 5
Infliximab, n 238 1 1
Table 2: Improvement in DAS 28 and HAQ, and DAS-28-based EULAR response in patients switching between TNF antagonists
1st TNF antagonist 2nd TNF antagonist 3rd TNF antagonist
Initial Final Δ p Initial Final Δ p Initial Final Δ P
DAS-28 5.9 3.3 -2.6 <0.0001 5.1 4.2 -1.1 0.0001 6.1 5.4 -0.7 0.06
HAQ 1.61 1.12 -0.49 <0.0001 1.52 1.31 -0.21 <0.004 1.87 1.75 -0.12 0.1
Good (%)* 174(42) 17(20) 5(28)
Moderate (%)* 138(33) 20(27)
No response (%)* 105(25) 44(53) 13(72)
* DAS-28-based EULAR responseBMC Musculoskeletal Disorders 2009, 10:91 http://www.biomedcentral.com/1471-2474/10/91
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tion of patients have marginal or no clinical
improvement. Improvement is generally negligible in
patients switching to a third biologic. Interestingly,
patients switching to a third TNF antagonist were younger,
more frequently female, and had a higher prevalence of
erosions despite the fact that disease duration was similar
to the other patients. This group probably represents a
subset of patients with more severe disease which is resist-
ant to these biologics.
Up to September 2008, there were 35 reports in the liter-
ature [7-42] on switching between TNF antagonists in RA
patients who experience treatment failure. Twenty reports
were based on observational studies, 10 on case series and
6 on prospective cohorts from biologic registries. Addi-
tionally there were 2 randomized clinical trials [8,11]: 1
double-blind and 1 open-label study. The two clinical tri-
als demonstrate the efficacy of switching between TNF
antagonists. On the whole, the numerous design limita-
tions of the other studies limit their value. Nevertheless,
the vast majority of them report on the favourable efficacy
of switching, yet information on the effect size is largely
unreported.
Most patients included in previous publications were
women (83%, range: 60–100), with an average age of 52
years (range: 32–68), and a disease duration of 12 years
(range: 3–27). When reported at baseline, mean DAS was
5.6 (range: 2.4–6.8), and mean HAQ 1.7 (range: 1.5–1.9).
This baseline information is no different from what was
found in our study. Of note, few publications report on
DAS-28 effect size, DAS-based EULAR response and HAQ
improvement in patients switching between TNF antago-
nists in comparison with patients who retain the first
antagonist. A value of -0.22 in HAQ is considered the
minimum clinically important difference (MCID) in stud-
ies of responsiveness [43]. The size of improvement with
the first TNF antagonist (-0.40) is within the range of what
has been reported in clinical trials [44-46]. Two-thirds of
patients treated with the first and less than half of those
treated with the second TNF antagonist had a MCID in
HAQ. Despite long-standing disease, HAQ improvement
was parallel to DAS-28 improvement, a result that was
unanticipated based on previous data [47].
Three studies [14,15,20] have described retention rates of
a second TNF antagonist as a surrogate for effectiveness.
Overall, the probability of retaining a second TNF antago-
nist was lower than retaining the first one. The probability
was influenced by the reason for drug replacement, i.e.
drug failure or adverse event. Interestingly, the reasons for
stopping a second drug were related to the reasons for
stopping the first drug [15]. Although the retention rate of
a drug can be taken as a reasonable indicator of its effec-
tiveness, parameters other than efficacy and safety, such as
co-morbidity, co-medications, costs, availability of other
therapies, patients' and physicians' expectations, and
adherence to treatment could influence drug survival. In
our study, retention rates of the second and third TNF
antagonists were within the boundaries of what other
authors have reported, suggesting that these rates are con-
sistently found in clinical practice. Herein, we show that
lack of response to a first TNF antagonist does not predict
the response to a second one, yet the efficacy of a second
TNF antagonist is inferior to that of the first.
Conclusion
A significant treatment effect size with a second TNF
antagonist in RA patients failing to respond to the first one
is limited to less than half of those treated. Furthermore,
RA patients who are refractory to TNF-antagonist treat-
ment have a poorer response to rituximab, abatacept and
tocilizumab than patients who are naive to biological
drugs. Evidence that the efficacy of cycling between TNF
antagonists is similar or superior to switching to the new
biologics is largely missing. The results reported by other
authors [48] as well as those of our own study suggest that
this may not be the case.
Table 3: DAS-28-based EULAR response in patients switchingto 
a second TNF antagonist, by reason for switching
Inefficacy
N (%)
Adverse events
N (%)
Other reasons
N (%)
Good 10 (20) 6 (25) 1 (10)
Moderate 12 (25) 8 (30) 2 (18)
No response 26 (55) 10 (45) 8 (72)
Mean cumulative change in HAQ from starting therapy in  patients with rheumatoid arthritis following cycling between  TNF antagonists. Figure 1
Mean cumulative change in HAQ from starting ther-
apy in patients with rheumatoid arthritis following 
cycling between TNF antagonists.
3rd TNF  
antagonist 
2nd TNF  
antagonist  
1st  TNF  
antagonist BMC Musculoskeletal Disorders 2009, 10:91 http://www.biomedcentral.com/1471-2474/10/91
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